RARE   $47.2  2.56% Market Closed After Close 47.24 0.08%

Ultragenyx Pharmaceutical Inc
Total Cash
totalCashPerShare
EBITDA -500.94M
Total Debt
quickRatio
currentRatio
Total Revenue 522.74M
debtToEquity 214.269
Revenue/Share 6.015
ROA
ROE
grossProfits
freeCashflow
operatingCashflow
earningsGrowth
revenueGrowth 0.423
grossMargins -0.37798
ebitdaMargins -0.95829004
operatingMargins -0.94618
profitMargins -1.06933
enterpriseValue
forwardPE -9.901328
floatShares 79.42M
sharesOutstanding 92.17M
sharesShort 3.16M
sharesShortPriorMonth 3.61M
dateShortInterest
sharesPercentSharesOut 0.03%
heldPercentInsiders 0.04%
heldPercentInstitutions 1.00%
Short Ratio help_outline 4.84%
shortPercentOfFloat 0.04%
impliedSharesOutstanding
bookValue 3.346
Price To Book help_outline 15.59
earningsQuarterlyGrowth
netIncomeToCommon -558.99M
trailingEps -7.21%
forwardEps -5.27%
enterpriseToEbitda
lastDividendValue
lastDividendDate
currentQuarterEstimate -1.36 4Q 2024
institutionsCount 404
lastUpdated Nov. 6, 2024, 5:25 p.m.